Notably, PFS was significantly longer in patients with lower Gal-9 and higher IL-4 levels.<h4>Conclusions</h4>Plasma-based immune markers measured at the time of TKI resistance may help predict which patients with EGFR-mutant NSCLC will respond to subsequent ICI therapy. Here, LGALS9 is linked to non-small cell lung carcinoma.